Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylaxis of Cytomegalovirus Infection in Haploidentical Hematopoietic Progenitor Transplantation with Adoptive Cell Immunotherapy
2019-002311-26Phase 2Active
- Sponsor
- IDIVAL
- Start
- Jan 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic cytomegalovirus-specific memory T cells in cytomegalovirus disease (CMV), sponsored by IDIVAL. Primary endpoints: Incidence of CMV infection at 100 days post-transplant and Need for treatment for CMV infection. Started Jan 2020; status: active.
02
Drugs
allogeneic cytomegalovirus-specific memory T cells
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2019-002311-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002311-26.